

# AI by the Numbers: Quantified Impact on Regulatory Workflows in Clinical Development

Daniel Pointing – Associate Director, Business Development



WEAVE.BIO



# About Weave

Diverse  
Customers

- Top 20 Pharma
- Mid-size therapeutics
- Small + startup biotech
- Global CROs
- CDMOs

\$36 Million  
Raised

- USVP
- Innovation Endeavors
- Magnetic Ventures
- Character
- TMV



# Our perspective

1. Document workflows sit on the critical path
2. Much of the work is still manual
3. This creates delays and variability



# Timeline allocation today vs ideal

## TODAY


- 🕒 Drafting & re-drafting
- 🕒 Formatting & QC
- 🕒 Aligning across teams
- 🕒 Review cycles

## IDEAL

- 🧠 Study design
- 🧠 Interpreting results
- 🧠 Clinical decisions
- 🧠 Planning next steps


Shifting effort, not replacing expertise

# Where AI actually helps (and where it doesn't)



# Where this work shows up

These workflows are still largely manual—and remain on the critical path



# What changed



Drafting  
time



Review  
cycles



Timeline  
predictability




## WEAVE + TAKEDA

# Drafting time


## MANUAL → WEAVE

- 2 historical INDs
- 100 first draft study summaries
- Pharmacology, PK, toxicology



## TIME


100 hours (Manual)  
→ **3 HOURS** (Weave, 97% faster)



WEAVE + TAKEDA

# Quality & consistency

## QUALITY



# Review cycles

Fewer iteration loops, faster alignment across teams  
Reduced iteration cycles (e.g., 5–7 → 2–3)

## QC/REVIEW EVERY DRAFT

Study Summary

2.6.6 Toxicology  
written summary

Auto-Review

## A NARRATIVE FOR EVERY OUTCOME

Template > Source Files

tox|

13F\_SFA\_repeat\_tox.pdf

13F\_SFA\_single\_tox.pdf

Study Summary [ver. 1]

Study Summary [ver. 2]

Study Summary [ver. 3]

2.6.6 Toxicology  
written summary

Select Version


## WRITE TO THINK

Prompt

Include the 10 mg/kg  
dose group.|

Refine

# Lifecycle from beginning to end



Hands-on time  
savings

50%

IND prep  
acceleration

66%

NDA (2.3)  
timeline  
acceleration

60%

parexel®

**Real-world impact**

*Faster timelines with consistent quality*

Contract to  
draft IND

2 weeks

Submission-  
ready IND

50 days



“I’ve been able to put my time towards other things that are essential to our success.”

- Nathan McMahon, PhD, Director of Clinical Operations

Reports to  
draft IND

<1 day

Users

20


enveda<sup>®</sup>



“It was done at record speed.”

- Niranjan Rao, PhD, FCP, Chief Development Officer

# A how-to guide



Start small, measure impact, then expand

# Thank you.

Visit us @ booth #13



Please reach out with  
questions or comments:

[daniel@weave.bio](mailto:daniel@weave.bio)

WEAVE.BIO